Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.58 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886645 | 1.00 | HRH3 (0.58) | HRH3PDE5ACYP11B2HPGDPKM | |
| SCHEMBL2884832 | 0.91 | HRH3 (0.59) | HRH3HPGD | |
| SCHEMBL2884382 | 0.88 | HRH3 (0.60) | HRH3HPGD | |
| SCHEMBL2885521 | 0.88 | HRH3 (0.75) | HRH3CYP11B2SMN1; SMN2 | |
| SCHEMBL2884787 | 0.88 | HRH3 (0.75) | HRH3CYP11B2SMN1; SMN2 | |
| SCHEMBL2885914 | 0.88 | HRH3 (0.75) | HRH3CYP11B2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2883590 | 0.87 | HRH3 (0.74) | HRH3CYP11B2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2886522 | 0.87 | HRH3 (0.74) | HRH3CYP11B2SMN1; SMN2 | |
| SCHEMBL2883568 | 0.87 | HRH3 (0.76) | HRH3 | |
| SCHEMBL2881996 | 0.87 | HRH3 (0.76) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | claimed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HRH3 3/4885PDE5A 1696/4885CYP11B2 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.